Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis

@article{Sekiguchi2006EfficacyAS,
  title={Efficacy and safety of bucillamine, a d-penicillamine analogue, in patients with active rheumatoid arthritis},
  author={Naoya Sekiguchi and Hideto Kameda and Koichi Amano and Tsutomu Takeuchi},
  journal={Modern Rheumatology},
  year={2006},
  volume={16},
  pages={85-91}
}
Japanese rheumatologists consider bucillamine (Buc) to be a useful disease-modifying antirheumatic drug (DMARD) and often give Buc to patients with rheumatoid arthritis (RA) prior to administering methotrexate (MTX). However, no large studies on the efficacy and safety of Buc in RA patients have been published in English to date. We therefore investigated the clinical course of RA patients treated with Buc and compared the results with those for patients treated with MTX to evaluate and confirm… Expand
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA
TLDR
Responses to Buc treatment were better in males, patients with shorter duration of illness, and those who were rheumatoid factor-negative, and data support Buc as a candidate for being a first-line drug for the treatment of patients with RA. Expand
Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA
Abstract Bucillamine (Buc) is a disease-modifying antirheumatic drug (DMARD) developed in Japan, which has been used as one of the first-line DMARDs for the treatment of rheumatoid arthritis (RA) inExpand
A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)
TLDR
From the efficacy and safety viewpoints alike, BUC was useful as first-choice treatment for early RA. Expand
A multicentre trial of bucillamine in the treatment of early rheumatoid arthritis (SNOW study)
Abstract In this study, we enrolled early rheumatoid arthritis (RA) patients at multiple institutes who fulfilled the American Rheumatism Association 1987 revised criteria for the classification ofExpand
The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study
TLDR
The usefulness of bucillamine as a second-line DMARD was demonstrated and there was no increase in risk of serious adverse effects related to previous DMARDs. Expand
The efficacy and safety of bucillamine as a second-line DMARD in the treatment of rheumatoid arthritis: a retrospective cohort study
Abstract We investigated the efficacy and safety of bucillamine administered as a second-line DMARD compared to administration as a first-line DMARD in the treatment of rheumatoid arthritis (RA). WeExpand
Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial
TLDR
DMARDs combination therapy may be a better treatment strategy than MTX monotherapy for maintaining RA control after successful discontinuation of biological agents. Expand
Acute interstitial nephritis with membranous nephropathy in bucillamine-treated rheumatoid arthritis
TLDR
Given the host of pathological findings that tend to develop in patients using bucillamine, patients receiving the drug who present with symptoms of acute kidney injury should undergo a renal biopsy to determine the presence of AIN. Expand
The Japanese experience with biologic therapies for rheumatoid arthritis
TLDR
Post-marketing surveillance data have been collected for all patients with RA who were treated with biologic agents in Japan to monitor drug safety and clearly demonstrated that only ∼5% of these patients experienced adverse drug reactions toBiologic agents, which were well tolerated. Expand
c basis for the effi cacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis
Finding a means to ameliorate and prevent bone destruction is one of the urgent issues in the treatment of rheumatoid arthritis. Recent studies revealed boneresorbing osteoclasts to be essential forExpand
...
1
2
3
...

References

SHOWING 1-10 OF 15 REFERENCES
Therapeutic effects of the combination of methotrexate and bucillamine in early rheumatoid arthritis: a multicenter, double-blind, randomized controlled study
TLDR
It was concluded that the combination therapy with MTX and BUC showed significantly higher clinical efficacy than either of the single DMARD therapies. Expand
A comparison between bucillamine and d-penicillamine in the treatment of rheumatoid arthritis
TLDR
In conclusion, bucillamine was as effective as d-penicillamine in the treatment of rheumatoid arthritis, and with the former the frequency of side effects tended to be lower. Expand
Factors predicting the response to low-dose methotrexate therapy in patients with rheumatoid arthritis: a better response in male patients
TLDR
Around 8mg/week of MTX was effective in half of the RA patients in the current study, and male sex was the only factor associated with a good response to MTX from a multivariate regression model analysis. Expand
The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis.
TLDR
Toxicity was noted at some time in 26 of 29 patients (90%), but reactions universally became mild and tolerable after adjustment of the dosage, and there was a significant reduction in mean prednisone dosage. Expand
Adverse effects of low dose methotrexate therapy in rheumatoid arthritis.
TLDR
The risk of treatment termination was 75% in patients with RA taking MTX after 60 months, and an adverse drug effect is a more common reason for treatment termination than loss/lack of beneficial effect or other reasons or lost to followup. Expand
[A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine].
TLDR
It is believed that this is the only reported case of pathologically proven bucillamine-induced interstitial pneumonitis, in which a surgical lung biopsy was performed. Expand
D-penicillamine: chemistry and clinical use in rheumatic disease.
TLDR
The discovery of D-penicillamine and its uses in medicine, including dosages, clinical and laboratory responses, patterns of adverse side effects or toxicity, drug-induced autoimmune diseases, indications and contraindications, and the monitoring and management of patients are reviewed. Expand
Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction.
TLDR
A 49-year-old Japanese man with rheumatoid arthritis acutely developed a skin eruption and severe non-productive cough seventeen days after the administration of leflunomide and finally died of respiratory failure 128 days afterThe onset of acute interstitial pneumonia. Expand
Photo-Induced Stevens–Johnson Syndrome Due to Sulfasalazine Therapy
TLDR
It seems that there was a correlation between the time course of the reaction and the administration of sulfasalazine, and an objective causality assessment revealed that the adverse effect was possible. Expand
[How Japanese clinicians treat rheumatoid arthritis (RA): a survey at the 44th annual meeting of Japan Rheumatism Association in 2000].
TLDR
There was a great variation among Japanese clinicians in the management of RA, and these results might be associated with poor outcomes of RA patients in Japan. Expand
...
1
2
...